This is a randomized, double blind, placebo and active (moxifloxacin open label) controlled
study in healthy subjects to assess the effect of the supratherapeutic exposure of
omaveloxolone on QTc interval. Moxifloxacin will be used as an active control and will be
administered as open label. Omaveloxolone and placebo will be administered in a blinded
fashion. All treatments will be administered after an FDA high-fat meal. Concentration-QTc
(C-QTc) analysis is the primary analysis for the study.